Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of HRS-9813 in pulmonary fibrosis
CTR20253837Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-9813 in idiopathic pulmonary fibrosis (IPF), pulmonary fibrosis (PF), sponsored by Hengrui Therapeutics. Started Nov 2025; status: active.
02
Drugs
HRS-9813
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on CTR20253837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253837.